European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Indications:1
KISQALI® (ribociclib) is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist
KISQALI is not recommended to be used in combination with tamoxifen.
To learn more about the safety profile of KISQALI, visit our portal page here.
For full safety profile information, please refer to the KISQALI Summary of Product Characteristics.
The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised tool that quantifies the likely magnitude of clinical benefit. The scale considers overall survival, progression-free survival, disease-free survival, hazard ratio, response rate, quality of life, prognosis of the condition and toxicity, of patients in the non-curative setting, ranging from grades 1 to 5, with 4 and 5 denoting substantial benefit.2
For further information, please refer to the ESMO-MCBS scorecard methodology.2
ESMO-MCBS: Scoring KISQALI
ESMO clinical practice guidelines:
KISQALI received an ESMO-MCBS rating of 5/5 when used in combination with LHRH and with ET3
ET is defined as NSAI or tamoxifen and LHRH
KISQALI + fulvestrant holds a rating of 4/5 as 1L/2L treatment of postmenopausal patients with HR+/HER2− aBC3
KISQALI + AI holds a rating of 4/5 as 1L treatment of postmenopausal patients with HR+/HER2− aBC3
The ESMO-MCBS was developed to promote the scientific integrity of ESMO and of oncologists, and in particular to:4
Reduce bias in data interpretation and analysis and enhance critical appraisal of the evidence
Reduce hype
Provide robust validation with strict adherence to standards for ‘accountability for reasonableness’
Provide reliable and fair evaluation of benefit to assist in cancer planning, value-based priority setting and impact-oriented resource allocation decisions
Find out more about the overall survival data of KISQALI
Discover the quality of life data of KISQALI
An established safety profile with KISQALI + ET1,5,6
ET is defined as AI or fulvestrant and LHRH
KISQALI is not recommended to be used in combination with tamoxifen.1
Across all three MONALEESA trials, progression-free survival was the primary endpoint, overall survival and quality of life were the secondary endpoints.7–9
1L, first-line; 2L, second-line; aBC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ESMO-MCBS, European Society for medical oncology magnitude of clinical benefit scale; ET, endocrine therapy; HER2–, human epidermal growth receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone.
References:
KISQALI® (ribociclib) Summary of Product Characteristics.
European Society for Medical Oncology. ESMO-magnitude of clinical benefit scale. Available at: https://www.esmo.org/content/download/288502/5736211/1/esmo-mcbs-booklet.pdf [Accessed March 2025].
European Society for Medical Oncology. Ribociclib. Available at: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form%5BsearchText%5D=ribociclib [Accessed March 2025].
European Society for Medical Oncology. About the ESMO-MCBS. Available at: https://www.esmo.org/guidelines/esmo-mcbs/about-the-esmo-mcbs [Accessed March 2025].
Borstnar S, et al. Radiol Oncol 2022;65(2):238–247.
Jackisch C, et al. Poster presentation P4-01-01. San Antonio Breast Cancer Symposium 2022, 6–10 December. San Antonio, USA.
Hortobagyi GN, et al. N Engl J Med 2016;375(18):1738-1748.
Slamon DJ, et al. J Clin Oncol 2018;36(24):2465–2472.
Tripathy MD, et al. Lancet Oncol 2018;19(7):904–915.
UK | March 2025 | 442291
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.